Felicia S Falvella
Overview
Explore the profile of Felicia S Falvella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aloisio E, Chibireva M, Serafini L, Pasqualetti S, Falvella F, Dolci A, et al.
Arch Pathol Lab Med
. 2020 Jul;
144(12):1457-1464.
PMID: 32649222
Context.—: A relevant portion of coronavirus disease 2019 (COVID-19) patients develop severe disease with negative outcomes. Several biomarkers have been proposed to predict COVID-19 severity, but no definite interpretative criteria...
2.
Marano M, Serafinelli J, Cairoli S, Martinelli D, Pisani M, Palumbo G, et al.
Ther Drug Monit
. 2018 Apr;
40(4):386-388.
PMID: 29683873
Eltrombopag is an oral thrombopoietin receptor agonist approved for the treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP), who are more than 1 year old, and show poor response...
3.
Falvella F, Cheli S, Clementi E
Pharmacogenet Genomics
. 2017 Jan;
27(2):81-82.
PMID: 28059981
No abstract available.
4.
Pogliani L, Falvella F, Cattaneo D, Pileri P, Moscatiello A, Cheli S, et al.
Ther Drug Monit
. 2017 Jan;
39(2):197-201.
PMID: 28045861
Background: An involvement of selective serotonin reuptake inhibitors (SSRIs) in increasing the risk of malformations, neonatal withdrawal syndrome, has been suggested recently. Here, we aimed to investigate the contribution of...
5.
Antoniazzi S, Tatulli A, Falvella F, Cigliobianco M, Paoli R, Cattaneo D, et al.
J Clin Pharm Ther
. 2016 Nov;
42(1):119-121.
PMID: 27800629
What Is Known And Objective: Polymorphisms in cytochrome P450 2D6 and 2C19 can lead to interindividual differences in drug plasma concentrations, affecting clomipramine efficacy. Pharmacokinetic and pharmacogenetic analyses may improve...
6.
Cheli S, Pietrantonio F, Clementi E, Falvella F
Front Pharmacol
. 2015 Jun;
6:114.
PMID: 26082719
No abstract available.
7.
Falvella F, Alberio T, Noci S, Santambrogio L, Nosotti M, Incarbone M, et al.
Carcinogenesis
. 2013 Feb;
34(6):1281-5.
PMID: 23430818
CHRNA5 gene expression variation may play a role in individual susceptibility to lung cancer. Analysis of CHRNA5 transcripts expressed in normal lung tissue detected the full-length transcript (isoform-1) and four...
8.
Frullanti E, Colombo F, Falvella F, Galvan A, Noci S, De Cecco L, et al.
Int J Cancer
. 2012 Jan;
131(5):E643-8.
PMID: 22223368
Associations between clinical outcome of cancer patients and the gene expression signature in primary tumors at time of diagnosis have been reported. To test whether gene expression patterns in noninvolved...
9.
Colombo F, Falvella F, Galvan A, Frullanti E, Kunitoh H, Ushijima T, et al.
Mol Cancer
. 2011 Jul;
10:81.
PMID: 21736709
Background: The MFSD2A gene maps within a linkage disequilibrium block containing the MYCL1-EcoRI polymorphism associated with prognosis and survival in lung cancer patients. Survival discrepancies between Asians and Caucasians point...
10.
Galvan A, Skorpen F, Klepstad P, Knudsen A, Fladvad T, Falvella F, et al.
Clin Cancer Res
. 2011 May;
17(13):4581-7.
PMID: 21622719
Purpose: Patients treated with opioid drugs for cancer pain experience different relief responses, raising the possibility that genetic factors play a role in opioid therapy outcome. In this study, we...